Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.

The American journal of gastroenterology - 1 May 2018

Oduyebo Ibironke, Camilleri Michael, Nelson Alfred D, Khemani Disha, Nord Sara Linker, Busciglio Irene, Burton Duane, Rhoten Deborah, Ryks Michael, Carlson Paula, Donato Leslie, Lueke Alan, Kim Kathline, Rossi Stephen J, Zinsmeister Alan R

Abstract excerpt

OBJECTIVE: NGM282 is an analog of fibroblast growth factor 19 (FGF19), a potent inhibitor of bile acid (BA) synthesis in animals and humans. In phase 2 trials in type 2 diabetes and primary biliary cholangitis, NGM282 was associated with dose-related abdominal cramping and diarrhea. We aimed to examine effects of NGM282 on colonic transit, stool frequency and consistency, hepatic BA synthesis (fasting serum C4),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Appetite
Share to Bile Acids and Salts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Constipation

Share to Fibroblast Growth Factors

Share to Gastrointestinal Motility

Share to Injections, Subcutaneous

Share to Klotho Proteins

Share to Receptor, Fibroblast Growth Factor, Type 4

Source

Identifiers

PMID: 29717197
DOI: 10.1038/s41395-018-0042-7

Genes

FGF19
KLB
FGFR4
GPBAR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.PMID 29717197Read ↗

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.Semantic proximity Read ↗

Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.Semantic proximity Read ↗

Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit.Semantic proximity Read ↗

The role of FGF19 in the diagnosis and pathophysiology of primary bile acid diarrhoeaSemantic proximity Read ↗

Mechanisms of idiopathic bile acid malabsorption and diarrhoeaSemantic proximity Read ↗

Investigating Fibroblast Growth Factor 19 expression in primary and secondary bile acid diarrhoeaSemantic proximity Read ↗

A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.Semantic proximity Read ↗

Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.Semantic proximity Read ↗

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.Semantic proximity Read ↗

Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.Semantic proximity Read ↗

Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion.Semantic proximity Read ↗

Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.